Antisense oligonucleotide-mediated Dnm2 knockdown delays myotubular myopathy in mice after a single injection

Centronuclear myopathies (CNM) are non-dystrophic muscle diseases for which no effective therapy is currently available. The most severe form, X-linked CNM, is caused by myotubularin 1 (MTM1) loss-of-function mutations, while the main autosomal dominant form is due to dynamin2 (DNM2) mutations. We previously showed that genetic reduction of DNM2 expression in Mtm1 knockout (Mtm1KO) mice prevents development of muscle pathology. Most recently we have shown that weekly systemic delivery of Dnm2 antisense oligonucleotides (ASOs) into Mtm1KO mice efficiently reduces DNM2 protein level in muscle and prevents the myopathy from developing.

Source: Neuromuscular Disorders - September 10, 2017 Category: Neurology Authors: S. Buono, C. Kretz, C. Koch, A. Rob é, S. Guo, B. Monia, J. Laporte, L. Thielemans, B. Cowling Source Type: research